First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation

被引：7
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, Dept Chem, San Diego, CA 92121 USA
[2] Bharath Univ, Chennai 600126, Tamil Nadu, India
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 03期
关键词：
Non-small cell lung cancer; KRAS mutation; guanosine triphosphate; guanosine diphosphate; adagrasib; sotorasib; RESISTANCE; RAS;
D O I：
10.2174/0929867330666230330122000
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Adagrasib is an orally bioavailable, highly selective, small-molecule, irreversible covalent inhibitor of KRAS(G12C). It was approved by the US FDA on December 12, 2022, for patients with tumors harboring the KRAS(G12C )mutation in locally advanced or metastatic non-small cell lung cancer (NSCLC). Herein, synthesis, dosage and administration, mechanism of action, pharmacokinetics, pharmacodynamics, and adverse events of adagrasib are described.
引用
收藏
页码：266 / 272
页数：7
相关论文
共 50 条
  • [21] KRASG12C mutation in metastatic colorectal cancer: a new target
    Ibrahim, Rebecca
    Saleh, Khalil
    Chahine, Claude
    Khoury, Rita
    Khalife, Nadine
    Lecesne, Axel
    FUTURE ONCOLOGY, 2023, 19 (24) : 1641 - 1643
  • [22] CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer
    Prahallad, Anirudh
    Weiss, Andreas
    Voshol, Hans
    Kerr, Grainne
    Sprouffske, Kathleen
    Yuan, Tina
    Ruddy, David
    Meistertzheim, Morgane
    Kazic-Legueux, Malika
    Kottarathil, Tina
    Piquet, Michelle
    Cao, Yichen
    Martinuzzi-Duboc, Laetitia
    Buhles, Alexandra
    Adler, Flavia
    Mannino, Salvatore
    Tordella, Luca
    Sansregret, Laurent
    Maira, Sauveur-Michel
    Graus Porta, Diana
    Fedele, Carmine
    Brachmann, Saskia M.
    CANCER RESEARCH, 2023, 83 (24) : 4130 - 4141
  • [23] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Di Federico, Alessandro
    Ricciotti, Ilaria
    Favorito, Valentina
    Michelina, Sandra Vietti
    Scaparone, Pietro
    Metro, Giulio
    De Giglio, Andrea
    Pecci, Federica
    Lamberti, Giuseppe
    Ambrogio, Chiara
    Ricciuti, Biagio
    CURRENT ONCOLOGY REPORTS, 2023, 25 (09) : 1017 - 1029
  • [24] RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
    Wu, Jianzhuang
    Xie, Kexin
    Zhang, Yixuan
    Zhang, Weiyi
    Cheng, Rongjie
    Zhang, Yaliang
    Xia, Yugui
    Liu, Tongyan
    Yin, Rong
    Qiu, Yudong
    Xu, Tao
    Li, Rutian
    Sun, Qi
    Yan, Chao
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2025, 44 (01)
  • [25] Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
    Shin, Hyungkyung
    Hwang, Sua
    Jeong, Jeong Hyun
    Shin, Sang Chul
    Oh, Yeonji
    Kim, Jinhyeok
    Hwang, Inah
    Kim, Eunice EunKyeong
    Choo, Hyunah
    Song, Eun Joo
    PHARMACOLOGICAL RESEARCH, 2025, 215
  • [26] Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
    Takahisa Kawamura
    Hirotsugu Kenmotsu
    Haruki Kobayashi
    Shota Omori
    Kazuhisa Nakashima
    Kazushige Wakuda
    Akira Ono
    Tateaki Naito
    Haruyasu Murakami
    Keita Mori
    Masahiro Endo
    Toshiaki Takahashi
    Investigational New Drugs, 2020, 38 : 194 - 201
  • [27] Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
    Kawamura, Takahisa
    Kenmotsu, Hirotsugu
    Kobayashi, Haruki
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Mori, Keita
    Endo, Masahiro
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 194 - 201
  • [28] Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    Chantharasamee, J.
    Poungvarin, N.
    Danchaivijitr, P.
    Techawatanawanna, S.
    BMC CANCER, 2019, 19 (1)
  • [29] Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
    Alessandro Di Federico
    Ilaria Ricciotti
    Valentina Favorito
    Sandra Vietti Michelina
    Pietro Scaparone
    Giulio Metro
    Andrea De Giglio
    Federica Pecci
    Giuseppe Lamberti
    Chiara Ambrogio
    Biagio Ricciuti
    Current Oncology Reports, 2023, 25 : 1017 - 1029
  • [30] Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer
    De, Surya K. K.
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (09) : 1000 - 1002
12345